Aclaris Therapeutics (NASDAQ: ACRS) — Perfil da empresa, notícias e dados financeiros
Aclaris Therapeutics develops novel dermatological therapies to address immuno-inflammatory skin conditions.

Aclaris Therapeutics
Aclaris Therapeutics (NASDAQ:ACRS) specializes in developing novel drug candidates and therapies in dermatology and immunology. The company focuses on addressing unmet needs for patients with conditions stemming from immuno-inflammatory responses. Aclaris is actively involved in a range of projects, emphasizing innovation in the treatment of skin diseases and hair loss, among other health concerns. Their objectives include advancing their pipeline products through clinical trials with the goal of achieving market approval and creating effective treatments that improve patients' quality of life. Through rigorous research and development efforts, Aclaris aims to bring transformative therapies to the market, targeting conditions with significant patient impact.
Resumo
Operações
Produtos e/ou serviços de Aclaris Therapeutics
- ATI-450, an oral MK2 inhibitor for treating rheumatoid arthritis.
- A-101 45% Topical Solution for common warts (verruca vulgaris).
- ATI-1777, an investigational soft JAK 1/3 inhibitor applied topically for atopic dermatitis.
- ATI-2138, an oral ITK inhibitor for T-cell mediated diseases, including psoriasis.
equipe executiva do Aclaris Therapeutics
- Neal S. WalkerCo-Founder, CEO & Chairman
- Hugh M. DavisPresident, COO & Director
- Kevin BalthaserChief Financial Officer
- James LoeropChief Business Officer
- Roland KolbeckChief Scientific Officer
- William C. RobertsSenior Vice President of Corporate Communications & Investor Relations
- Matthew RothmanGeneral Counsel & Corporate Secretary
- Steve TuckerExecutive Vice President of Project Leadership
- Jesse W. HallChief Medical Officer
- Nina SamraSenior Vice President of Clinical Operations
Últimas notícias sobre a Aclaris Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Aclaris Therapeutics, em USD.
- Cap. de mercado
- 557,9 mi
- Receita (TTM)
- 8,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,8 mi | -76,4 mi | -64,9 mi | |
| 18,7 mi | -141,9 mi | -132,1 mi | |
| 31,2 mi | -97,4 mi | -88,5 mi | |
| 29,8 mi | -89,9 mi | -86,9 mi |